Category: JCN Newswire

Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status

TOKYO and CAMBRIDGE, Mass., Sept. 3, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that Eisai

More

TANAKA Memorial Foundation to Offer Precious Metals Research Grants of Up to 10 Million Yen (from a Grant Pool of 20 Million Yen) – Applications for Research Projects Open on September 1

TOKYO, Sept 1, 2025 – (JCN Newswire via SeaPRwire.com) – TANAKA Memorial Foundation (Representative Director: Hideya Okamoto) has announced that it will be accept applications for research themes for FY2025 Precious Metals Research Grants from September 1 to November 28, 2025.

More

Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma

TOKYO, August 29, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has received orphan drug designation for anticancer agent the EZH2*1 inhibitor tazemetostat hydrobromide (generic name, product name

More

Production, Sales and Export Results for July, 2025

TOKYO, Japan, August 28, 2025 – (JCN Newswire via SeaPRwire.com) – Honda Motor Co., Ltd. today announced a summary of automobile production, Japan domestic sales, and export results for the month of July 2025. For more details, please visit: https://global.honda/content/dam/site/global-en/newsroom-new/cq_img/news/2025/08/c250828beng/c250828beng.pdf

More